Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Bioverativ: More Than Just A Hemophilia Company

Jan 22 2018

• By Jessica Merrill

John Cox at JPM — Bioverativ CEO John Cox

Related Content

Bicycle Partners With Biogen Spinout Against Rare Blood Disorders

Sep 06 2017

Bioverativ Hits The Street Ready To Expand In Blood Disorders

Jan 26 2017

Spark Plots Rebound For Hemophilia A Gene Therapy, As Rival BioMarin Surges

Dec 12 2017

Bioverativ Fills Gap In Pipeline With $400m True North Buy

May 23 2017

Sanofi Builds Blood Disorder Specialty With Bioverativ Buy

Jan 22 2018

Related Companies

Sanofi

Biogen, Inc.

Sanofi

Swedish Orphan Biovitrum AB

BioMarin Pharmaceutical Inc.

Spark Therapeutics, Inc.

True North Therapeutics, Inc.

Alexion Pharmaceuticals Inc.

Sangamo Therapeutics, Inc.

Bicycle Therapeutics, plc

Additional Topics

Business Strategies M & A Commercial Research & Development Blood & Coagulation Disorders BioPharmaceutical

More from Strategy

More from Business

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window